Physician profile
Darrick Li
NPI 1063825131
$28,208.68
in general payments reported to CMS, 2019-2025
30 companies · $7,410 in 2025
The $7,410 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,318 · 2024: $19K · 2025: $7,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $7,193 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,000.00 |
| Food and Beverage | $7,192.75 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $22,172.54 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,328.59 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $760.95 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $463.19 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $439.46 | 2023-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $407.44 | 2023-2025 | |
| Madrigal Pharmaceuticals | $368.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $308.01 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $192.40 | 2023-2025 | Ocaliva |
| Qol Medical, LLC | $183.12 | 2025 | Sucraid |
| Pfizer INC. | $173.92 | 2023-2025 | |
| Celgene Corporation | $165.35 | 2023-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $157.64 | 2023-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $145.79 | 2023 | |
| Celltrion USA INC. | $139.14 | 2025 | Vegzelma |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $130.64 | 2024 | Idacio |
| Braintree Laboratories, INC. | $85.28 | 2023-2024 | Sutab, Suflave |
| Lilly USA, LLC | $77.61 | 2024-2025 | Omvoh |
| Genzyme Corporation | $75.31 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $65.66 | 2024 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $57.99 | 2024 | Bylvay, Iqirvo |
| Exact Sciences Corporation | $53.53 | 2025 | Cologuard Collection Kit |
| Pentax of America, INC. | $46.07 | 2025 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Biocon Biologics INC | $44.33 | 2025 | Yesintek |
| Ferring Pharmaceuticals INC. | $42.74 | 2025 | Rebyota |
| Redhill Biopharma INC. | $34.32 | 2023 | Talicia |
| Novo Nordisk INC | $29.64 | 2025 | Wegovy |
| Axonics, INC. | $23.59 | 2024 | Axonics |
| Regeneron Healthcare Solutions, INC. | $21.74 | 2025 | Dupixent |
| Evoke Pharma, INC. | $13.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrick Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.